Physician profile
Anthony M Ruffa
NPI 1134128341
$6,552.83
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,856 · 2020: $2,582 · 2021: $69.35 · 2022: $14.02 · 2023: $13.91 · 2024: $17.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,175.37 | 2019-2020 | |
| Pfizer INC. | $882.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $823.90 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.73 | 2019-2021 | |
| Amgen INC. | $424.50 | 2019-2020 | |
| Daiichi Sankyo INC. | $337.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $300.97 | 2019-2020 | |
| Gilead Sciences, INC. | $278.62 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $244.63 | 2019-2020 | |
| Novo Nordisk INC | $229.35 | 2019-2022 | |
| Lilly USA, LLC | $222.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $218.57 | 2019-2020 | |
| Amarin Pharma, INC. | $184.75 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $169.16 | 2019-2021 | |
| Grifols USA, LLC | $147.11 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $112.34 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.92 | 2020 | |
| Sanofi Pasteur INC. | $62.09 | 2019-2020 | |
| Pacira Therapeutics, INC. | $61.11 | 2019-2020 | |
| Abbvie INC. | $45.94 | 2019 | |
| Braeburn INC. | $17.93 | 2024 | Brixadi |
| Valeritas, INC. | $16.28 | 2019 | |
| Shire North American Group INC | $15.64 | 2019 | |
| Boston Scientific Corporation | $13.91 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ruffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.